Enclave Advisors LLC Boosts Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Enclave Advisors LLC lifted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 24.5% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 488 shares of the biopharmaceutical company’s stock after acquiring an additional 96 shares during the quarter. Enclave Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $310,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Pinney & Scofield Inc. purchased a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth about $25,000. OFI Invest Asset Management purchased a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth about $28,000. Rakuten Securities Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 62.5% during the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 15 shares in the last quarter. Tompkins Financial Corp purchased a new position in Regeneron Pharmaceuticals in the 1st quarter valued at about $32,000. Finally, Avalon Trust Co purchased a new position in Regeneron Pharmaceuticals in the 4th quarter valued at about $36,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Down 0.4%

Shares of NASDAQ REGN opened at $483.07 on Friday. The company has a 50 day simple moving average of $572.23 and a 200-day simple moving average of $659.43. The company has a market capitalization of $52.15 billion, a P/E ratio of 12.62, a P/E/G ratio of 2.34 and a beta of 0.31. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $8.83 by ($0.61). The firm had revenue of $3.03 billion for the quarter, compared to analyst estimates of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm’s quarterly revenue was down 3.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $9.55 EPS. On average, equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 20th will be issued a $0.88 dividend. The ex-dividend date of this dividend is Tuesday, May 20th. This represents a $3.52 annualized dividend and a yield of 0.73%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 8.96%.

Analyst Ratings Changes

A number of research analysts recently weighed in on REGN shares. Morgan Stanley decreased their price target on shares of Regeneron Pharmaceuticals from $958.00 to $755.00 and set an “overweight” rating on the stock in a research note on Monday. Guggenheim reaffirmed a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Friday, May 30th. Robert W. Baird decreased their price target on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a “neutral” rating on the stock in a research note on Friday, April 25th. Citigroup decreased their price target on shares of Regeneron Pharmaceuticals from $700.00 to $650.00 and set a “buy” rating on the stock in a research note on Monday. Finally, Wall Street Zen lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, May 1st. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $844.48.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.